Alvotech develops and manufactures biosimilar medicines, sold through pharmaceutical partners to patients worldwide. ALVO reports earnings on Wed, Nov 11, 2026. In the past 30 days there were 2 dark pool prints.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 16 | Barclays | Upgrade | Buy | |
| Aug 24 | B of A Securities | Initiated | Buy |
Seasonality
How ALVO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.
Whale Options Flow
90DNo whale options trades in ALVO in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALVO is in one of them and how their past ALVO trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ALVO in an article yet. Here's the latest on the wider market.
About Alvotech
Alvotech is a biotechnology company based in Luxembourg that develops and manufactures biosimilars, which are lower cost versions of established biologic medicines. Its approved products copy treatments for conditions such as arthritis, psoriasis, Crohn's disease, macular degeneration and osteoporosis. The company handles research, manufacturing and regulatory work in-house and licenses its products to pharmaceutical partners that sell them in global markets, serving patients worldwide.
- Headquarters
- Luxembourg, Luxembourg